12 Yue 3 izinsuku, isifundo esithi "The Lancet" esishicilelwe ku-inthanethi, se I-CD30 i-peripheral yangaphandle engaphandle T -Iziguli ze-lymphoma, le rituximab, i-cyclophosphamide, i-doxorubicin ne-prednisone ( I-A + CHP Kungcono kune-cyclophosphamide, doxorubicin, vincristine ne-prednisone ( CHOP ).
USteven Horwitz, MD, ovela eSikhumbuzo Sloan Kettering Cancer Center eNew York City kanye nozakwabo benze ucwaningo lwesigaba sesi-3 esilawulwa izimpumputhe, esilawulwa yi-placebo, esisebenza ngokulawula okubandakanya iziguli ezingama-452 ezivela ezindaweni eziyi-132 emazweni ayi-17. Lezi ziguli CD30- positive peripheral T- cell lymphoma ngaphandle kokwelashwa ngaphambi. Iziguli ezine-1: 1 isilinganiso esabiwe esingahleliwe, samukela i-A + CHP noma i-CHOP, igcinwe i-6, noma. 8 th 21 ngumjikelezo wosuku.
Abaphenyi bathole ukuthi ukusinda okungenamkhawulo okuqhubekayo (PFS) kweqembu le-A + CHP neqembu le-CHOP kwakuyizinyanga ezingama-48.2 no-20.8 ngokulandelana. Isimo semiphumela emibi besifana phakathi kwala maqembu womabili, kufaka phakathi i-febrile neutropenia (18% no-15%, ngokulandelana) kanye ne-peripheral neuropathy (52% no-55%, ngokulandelana). Imicimbi emibi ebulalayo yenzeke ku-3% naku-4% weziguli, ngokulandelana.
In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for i-lymphoma iziguli.
